{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T19:26:56Z","timestamp":1791401216416,"version":"4.3.3"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2025,1,3]],"date-time":"2025-01-03T00:00:00Z","timestamp":1735862400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,1,3]],"date-time":"2025-01-03T00:00:00Z","timestamp":1735862400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Ministry of Education, Culture, Sports, Science and Technology, Japan Society for Promotion of Science","award":["(22K16876"],"award-info":[{"award-number":["(22K16876"]}]},{"name":"Seiichi Imai Memorial Foundation"},{"DOI":"10.13039\/501100004823","name":"Nagoya University","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100004823","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Immunol Immunother"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>We focused on how the immunophenotypes based on the distribution of CD8-positive tumor-infiltrating lymphocytes (TILs) relate to the endometrial cancer (EC) molecular subtypes and patients\u2019 prognosis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Patients and methods<\/jats:title>\n                    <jats:p>\n                      Two cohorts of EC patients (total\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u2009145) were analyzed and categorized using the Molecular Risk Classifier for Endometrial cancer (ProMisE): POLEmut (\n                      <jats:italic>POLE<\/jats:italic>\n                      mutation), MMRd (mismatch repair deficiency), NSMP (no specific molecular profile), and p53abn (p53 abnormality). CD8-positive TILs, within the central tumor and the invasive margin, were examined by using immunohistochemical staining and advanced image-analysis software. It was investigated whether these immunophenotypes correlate with the molecular subtypes and patients' survival. RNA-sequencing (RNA-seq) was used to explore tumor-derived factors influencing these immunophenotypes.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Three distinct immunophenotypes (inflamed, excluded, and desert) based on the CD8-positive TIL patterns were identified in EC patients. Notably, the inflamed phenotype was most frequently observed in the POLEmut and MMRd subtypes, while the desert phenotype was predominant in the NSMP subtype; however, other immunophenotypes were also observed. All p53abn subtype showed the non-inflamed (excluded or desert) phenotype. The prognosis was markedly poorer in the patients with the non-inflamed phenotype than in those with the inflamed phenotype. The RNA-seq analysis showed that the expression of\n                      <jats:italic>MYC<\/jats:italic>\n                      target genes and type-1 interferon response genes was enriched in the non-inflamed phenotype in MMRd and NSMP subtypes, respectively.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Evaluating not only the molecular classification but also the immunophenotype may lead to more personalized immunotherapy in EC and elucidating the mechanisms that underlie the formation of the three immunophenotypes could lead to the discovery of new immunotherapy targets.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s00262-024-03919-8","type":"journal-article","created":{"date-parts":[[2025,1,3]],"date-time":"2025-01-03T05:17:14Z","timestamp":1735881434000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Understanding the impact of spatial immunophenotypes on the survival of endometrial cancer patients through the ProMisE classification"],"prefix":"10.1007","volume":"74","author":[{"given":"Satomi","family":"Hattori","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nobuhisa","family":"Yoshikawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenting","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tetsuya","family":"Matsukawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mei","family":"Kubokawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kosuke","family":"Yoshida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masato","family":"Yoshihara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satoshi","family":"Tamauchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshiki","family":"Ikeda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akira","family":"Yokoi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yusuke","family":"Shimizu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaoru","family":"Niimi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroaki","family":"Kajiyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,1,3]]},"reference":[{"issue":"11","key":"3919_CR1","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1038\/s41571-024-00934-7","volume":"21","author":"JA How","year":"2024","unstructured":"How JA et al (2024) Translating biological insights into improved management of endometrial cancer. Nat Rev Clin Oncol 21(11):781\u2013800. https:\/\/doi.org\/10.1038\/s41571-024-00934-7","journal-title":"Nat Rev Clin Oncol"},{"issue":"7","key":"3919_CR2","doi-asserted-by":"publisher","first-page":"1234","DOI":"10.1200\/JCO.2004.08.159","volume":"22","author":"CL Creutzberg","year":"2004","unstructured":"Creutzberg CL et al (2004) Outcome of high-risk stage IC, grade 3, compared with stage I endometrial carcinoma patients: the postoperative radiation therapy in endometrial carcinoma trial. J Clin Oncol 22(7):1234\u20131241. https:\/\/doi.org\/10.1200\/JCO.2004.08.159","journal-title":"J Clin Oncol"},{"issue":"3","key":"3919_CR3","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1002\/IJGO.14033","volume":"158","author":"A Raffone","year":"2022","unstructured":"Raffone A et al (2022) Uterine carcinosarcoma vs endometrial serous and clear cell carcinoma: a systematic review and meta-analysis of survival. Int J Gynaecol Obstet 158(3):520\u2013527. https:\/\/doi.org\/10.1002\/IJGO.14033","journal-title":"Int J Gynaecol Obstet"},{"issue":"7447","key":"3919_CR4","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1038\/NATURE12113","volume":"497","author":"G Getz","year":"2013","unstructured":"Getz G et al (2013) Integrated genomic characterization of endometrial carcinoma. Nature 497(7447):67\u201373. https:\/\/doi.org\/10.1038\/NATURE12113","journal-title":"Nature"},{"issue":"14","key":"3919_CR5","doi-asserted-by":"publisher","first-page":"2409","DOI":"10.1002\/CNCR.33516","volume":"127","author":"JN McAlpine","year":"2021","unstructured":"McAlpine JN et al (2021) Evaluation of treatment effects in patients with endometrial cancer and POLE mutations: an individual patient data meta-analysis. Cancer 127(14):2409\u20132422. https:\/\/doi.org\/10.1002\/CNCR.33516","journal-title":"Cancer"},{"issue":"9","key":"3919_CR6","doi-asserted-by":"publisher","first-page":"2613","DOI":"10.1158\/1078-0432.CCR-20-4436","volume":"27","author":"A Momeni-Boroujeni","year":"2021","unstructured":"Momeni-Boroujeni A et al (2021) Clinicopathologic and genomic analysis of TP53-mutated endometrial carcinomas. Clin Cancer Res 27(9):2613\u20132623. https:\/\/doi.org\/10.1158\/1078-0432.CCR-20-4436","journal-title":"Clin Cancer Res"},{"issue":"2","key":"3919_CR7","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1038\/BJC.2015.190","volume":"113","author":"A Talhouk","year":"2015","unstructured":"Talhouk A et al (2015) A clinically applicable molecular-based classification for endometrial cancers. Br J Cancer 113(2):299\u2013310. https:\/\/doi.org\/10.1038\/BJC.2015.190","journal-title":"Br J Cancer"},{"issue":"5","key":"3919_CR8","doi-asserted-by":"publisher","first-page":"802","DOI":"10.1002\/CNCR.30496","volume":"123","author":"A Talhouk","year":"2017","unstructured":"Talhouk A et al (2017) Confirmation of ProMisE: a simple, genomics-based clinical classifier for endometrial cancer. Cancer 123(5):802\u2013813. https:\/\/doi.org\/10.1002\/CNCR.30496","journal-title":"Cancer"},{"issue":"5","key":"3919_CR9","doi-asserted-by":"publisher","first-page":"1180","DOI":"10.1093\/ANNONC\/MDY058","volume":"29","author":"S Kommoss","year":"2018","unstructured":"Kommoss S et al (2018) Final validation of the ProMisE molecular classifier for endometrial carcinoma in a large population-based case series. Ann Oncol 29(5):1180\u20131188. https:\/\/doi.org\/10.1093\/ANNONC\/MDY058","journal-title":"Ann Oncol"},{"key":"3919_CR10","doi-asserted-by":"publisher","DOI":"10.3802\/jgo.2023.34.e85","author":"JS Berek","year":"2023","unstructured":"Berek JS, Matias-Guiu X, Creutzberg C, Fotopoulou C, Gaffney D, Kehoe S, Lindemann K, Mutch D, Concin N (2023) FIGO staging of endometrial cancer: 2023. J Gynecol Oncol. https:\/\/doi.org\/10.3802\/jgo.2023.34.e85","journal-title":"J Gynecol Oncol"},{"issue":"5795","key":"3919_CR11","doi-asserted-by":"publisher","first-page":"1960","DOI":"10.1126\/SCIENCE.1129139","volume":"313","author":"J Galon","year":"2006","unstructured":"Galon J et al (2006) Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science 313(5795):1960\u20131964. https:\/\/doi.org\/10.1126\/SCIENCE.1129139","journal-title":"Science"},{"issue":"8","key":"3919_CR12","doi-asserted-by":"publisher","first-page":"1865","DOI":"10.1158\/1078-0432.CCR-15-1507","volume":"22","author":"PS Hegde","year":"2016","unstructured":"Hegde PS, Karanikas V, Evers S (2016) The where, the when, and the how of immune monitoring for cancer immunotherapies in the era of checkpoint inhibition. Clin Cancer Res 22(8):1865\u20131874. https:\/\/doi.org\/10.1158\/1078-0432.CCR-15-1507","journal-title":"Clin Cancer Res"},{"key":"3919_CR13","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-25962-0","author":"D Hammerl","year":"2021","unstructured":"Hammerl D, Martens JWM, Timmermans M, Smid M, Trapman-Jansen AM, Foekens R, Isaeva OI, Voorwerk L, Balcioglu HE, Wijers R, Nederlof I, Salgado R, Horlings H, Kok M, Debets R (2021) Spatial immunophenotypes predict response to anti-PD1 treatment and capture distinct paths of T cell evasion in triple negative breast cancer. Nat Commun. https:\/\/doi.org\/10.1038\/s41467-021-25962-0","journal-title":"Nat Commun"},{"key":"3919_CR14","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2020\/1805764","volume":"2020","author":"F Guo","year":"2020","unstructured":"Guo F, Dong Y, Tan Q, Kong J, Bin Yu (2020) Tissue infiltrating immune cells as prognostic biomarkers in endometrial cancer: a meta-analysis. Dis Mark 2020:1\u201311. https:\/\/doi.org\/10.1155\/2020\/1805764","journal-title":"Dis Mark"},{"key":"3919_CR15","doi-asserted-by":"publisher","DOI":"10.3802\/jgo.2020.31.e18","author":"W Yamagami","year":"2020","unstructured":"Yamagami W, Mikami M, Nagase S, Tabata T, Kobayashi Y, Kaneuchi M, Kobayashi H, Yamada H, Hasegawa K, Fujiwara H, Katabuchi H, Aoki D (2020) Japan society of gynecologic oncology 2018 guidelines for treatment of uterine body neoplasms. J Gynecol Oncol. https:\/\/doi.org\/10.3802\/jgo.2020.31.e18","journal-title":"J Gynecol Oncol"},{"issue":"3","key":"3919_CR16","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1007\/S10147-016-0981-1","volume":"21","author":"Y Ebina","year":"2016","unstructured":"Ebina Y et al (2016) Japan society of gynecologic oncology guidelines 2013 for the treatment of uterine body neoplasms. Int J Clin Oncol 21(3):419\u2013434. https:\/\/doi.org\/10.1007\/S10147-016-0981-1","journal-title":"Int J Clin Oncol"},{"issue":"9","key":"3919_CR17","doi-asserted-by":"publisher","first-page":"3134","DOI":"10.1111\/CAS.15460","volume":"113","author":"H Yamazaki","year":"2022","unstructured":"Yamazaki H et al (2022) The prognosis of endometrial cancers stratified with conventional risk factors and modified molecular classification. Cancer Sci 113(9):3134\u20133147. https:\/\/doi.org\/10.1111\/CAS.15460","journal-title":"Cancer Sci"},{"issue":"3","key":"3919_CR18","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1002\/PATH.5372","volume":"250","author":"A Le\u00f3n-Castillo","year":"2020","unstructured":"Le\u00f3n-Castillo A et al (2020) Interpretation of somatic POLE mutations in endometrial carcinoma. J Pathol 250(3):323\u2013335. https:\/\/doi.org\/10.1002\/PATH.5372","journal-title":"J Pathol"},{"issue":"5","key":"3919_CR19","doi-asserted-by":"publisher","first-page":"409","DOI":"10.3109\/00313025.2010.493871","volume":"42","author":"G Hall","year":"2010","unstructured":"Hall G et al (2010) Immunohistochemistry for PMS2 and MSH6 alone can replace a four antibody panel for mismatch repair deficiency screening in colorectal adenocarcinoma. Pathology 42(5):409\u2013413. https:\/\/doi.org\/10.3109\/00313025.2010.493871","journal-title":"Pathology"},{"issue":"9","key":"3919_CR20","doi-asserted-by":"publisher","first-page":"1248","DOI":"10.1038\/MODPATHOL.2011.85","volume":"24","author":"A Yemelyanova","year":"2011","unstructured":"Yemelyanova A et al (2011) Immunohistochemical staining patterns of p53 can serve as a surrogate marker for TP53 mutations in ovarian carcinoma: an immunohistochemical and nucleotide sequencing analysis. Mod Pathol 24(9):1248\u20131253. https:\/\/doi.org\/10.1038\/MODPATHOL.2011.85","journal-title":"Mod Pathol"},{"issue":"6","key":"3919_CR21","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1097\/PAP.0000000000000161","volume":"24","author":"S Hendry","year":"2017","unstructured":"Hendry S et al (2017) Assessing tumor-infiltrating lymphocytes in solid tumors: a practical review for pathologists and proposal for a standardized method from the international immuno-oncology biomarkers working group: part 2: tils in melanoma, gastrointestinal tract carcinomas, non-small cell lung carcinoma and mesothelioma, endometrial and ovarian carcinomas, squamous cell carcinoma of the head and neck, genitourinary carcinomas, and primary brain tumors. Adv Anat Pathol 24(6):311\u2013335. https:\/\/doi.org\/10.1097\/PAP.0000000000000161","journal-title":"Adv Anat Pathol"},{"key":"3919_CR22","doi-asserted-by":"publisher","DOI":"10.1038\/S41598-017-17204-5","author":"P Bankhead","year":"2017","unstructured":"Bankhead P et al (2017) QuPath: open source software for digital pathology image analysis. Sci Rep. https:\/\/doi.org\/10.1038\/S41598-017-17204-5","journal-title":"Sci Rep"},{"issue":"3","key":"3919_CR23","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1038\/S41573-018-0007-Y","volume":"18","author":"J Galon","year":"2019","unstructured":"Galon J, Bruni D (2019) Approaches to treat immune hot, altered and cold tumours with combination immunotherapies. Nat Rev Drug Discov 18(3):197\u2013218. https:\/\/doi.org\/10.1038\/S41573-018-0007-Y","journal-title":"Nat Rev Drug Discov"},{"key":"3919_CR24","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1007\/978-1-4939-7493-1_12","volume":"1711","author":"B Chen","year":"2018","unstructured":"Chen B, Khodadoust MS, Liu CL, Newman AM, Alizadeh AA (2018) Profiling tumor infiltrating immune cells with CIBERSORT. Methods Mol Biol 1711:243\u2013259. https:\/\/doi.org\/10.1007\/978-1-4939-7493-1_12","journal-title":"Methods Mol Biol"},{"issue":"6","key":"3919_CR25","doi-asserted-by":"publisher","first-page":"1679","DOI":"10.1007\/S00262-020-02813-3","volume":"70","author":"B Willvonseder","year":"2021","unstructured":"Willvonseder B et al (2021) The immunologic tumor microenvironment in endometrioid endometrial cancer in the morphomolecular context: mutual correlations and prognostic impact depending on molecular alterations. Cancer Immunol Immunother 70(6):1679\u20131689. https:\/\/doi.org\/10.1007\/S00262-020-02813-3","journal-title":"Cancer Immunol Immunother"},{"key":"3919_CR26","doi-asserted-by":"publisher","first-page":"101759","DOI":"10.1016\/J.TRANON.2023.101759","volume":"37","author":"E Shang","year":"2023","unstructured":"Shang E et al (2023) Overexpression of CD99 is associated with tumor adaptiveness and indicates the tumor recurrence and therapeutic responses in gliomas. Transl Oncol 37:101759. https:\/\/doi.org\/10.1016\/J.TRANON.2023.101759","journal-title":"Transl Oncol"},{"issue":"20","key":"3919_CR27","doi-asserted-by":"publisher","first-page":"2229","DOI":"10.1080\/15384101.2023.2281816","volume":"22","author":"Z Zhao","year":"2023","unstructured":"Zhao Z et al (2023) Multi-omics integration analysis unveils heterogeneity in breast cancer at the individual level. Cell Cycle 22(20):2229\u20132244. https:\/\/doi.org\/10.1080\/15384101.2023.2281816","journal-title":"Cell Cycle"},{"issue":"1","key":"3919_CR28","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/S12885-021-08621-X\/FIGURES\/6","volume":"21","author":"Q Yu","year":"2021","unstructured":"Yu Q et al (2021) Upregulated NLGN1 predicts poor survival in colorectal cancer. BMC Cancer 21(1):1\u201311. https:\/\/doi.org\/10.1186\/S12885-021-08621-X\/FIGURES\/6","journal-title":"BMC Cancer"},{"issue":"2","key":"3919_CR29","doi-asserted-by":"publisher","first-page":"280","DOI":"10.3390\/CELLS11020280\/S1","volume":"11","author":"L Bizzozero","year":"2022","unstructured":"Bizzozero L et al (2022) Tumoral neuroligin 1 promotes cancer-nerve interactions and synergizes with the glial cell line-derived neurotrophic factor. Cells 11(2):280. https:\/\/doi.org\/10.3390\/CELLS11020280\/S1","journal-title":"Cells"},{"key":"3919_CR30","doi-asserted-by":"publisher","first-page":"805260","DOI":"10.3389\/FIMMU.2021.805260\/BIBTEX","volume":"12","author":"S Nadeau","year":"2022","unstructured":"Nadeau S, Martins GA (2022) Conserved and unique functions of Blimp1 in immune cells. Front Immunol 12:805260. https:\/\/doi.org\/10.3389\/FIMMU.2021.805260\/BIBTEX","journal-title":"Front Immunol"},{"key":"3919_CR31","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-35469-x","author":"Q Li","year":"2022","unstructured":"Li Q, Zhang L, You W, Jiali Xu, Dai J, Hua D, Zhang R, Yao F, Zhou S, Huang W, Yongjiu Dai Yu, Zhang TB, Qian X, Liyong Pu, Jing Xu, Xia Y, Zhang C, Tang J, Wang X (2022) PRDM1\/BLIMP1 induces cancer immune evasion by modulating the USP22-SPI1-PD-L1 axis in hepatocellular carcinoma cells. Nat Commun. https:\/\/doi.org\/10.1038\/s41467-022-35469-x","journal-title":"Nat Commun"},{"issue":"1","key":"3919_CR32","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/S12964-022-00845-Z\/FIGURES\/9","volume":"20","author":"R Zhang","year":"2022","unstructured":"Zhang R et al (2022) An NF-\u03baB\/OVOL2 circuit regulates glucose import and cell survival in non-small cell lung cancer. Cell Commun Signal 20(1):1\u201319. https:\/\/doi.org\/10.1186\/S12964-022-00845-Z\/FIGURES\/9","journal-title":"Cell Commun Signal"},{"issue":"27","key":"3919_CR33","doi-asserted-by":"publisher","first-page":"2200705","DOI":"10.1002\/ADVS.202200705","volume":"9","author":"X Zhang","year":"2022","unstructured":"Zhang X et al (2022) Transcriptional repression of aerobic glycolysis by OVOL2 in breast cancer. Adv Sci 9(27):2200705. https:\/\/doi.org\/10.1002\/ADVS.202200705","journal-title":"Adv Sci"},{"issue":"7","key":"3919_CR34","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1111\/GTC.12774","volume":"25","author":"T Moriguchi","year":"2020","unstructured":"Moriguchi T, Takai J (2020) Histamine and histidine decarboxylase: Immunomodulatory functions and regulatory mechanisms. Genes Cells 25(7):443\u2013449. https:\/\/doi.org\/10.1111\/GTC.12774","journal-title":"Genes Cells"},{"issue":"11","key":"3919_CR35","doi-asserted-by":"publisher","first-page":"1531","DOI":"10.1016\/j.stem.2022.09.009","volume":"29","author":"J Chen","year":"2022","unstructured":"Chen J et al (2022) Glioblastoma stem cell-specific histamine secretion drives pro-angiogenic tumor microenvironment remodeling. Cell Stem Cell 29(11):1531-1546.e7","journal-title":"Cell Stem Cell"}],"container-title":["Cancer Immunology, Immunotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-024-03919-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00262-024-03919-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-024-03919-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,9]],"date-time":"2025-02-09T20:10:18Z","timestamp":1739131818000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00262-024-03919-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,3]]},"references-count":35,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2025,2]]}},"alternative-id":["3919"],"URL":"https:\/\/doi.org\/10.1007\/s00262-024-03919-8","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-5241013\/v1","asserted-by":"object"}]},"ISSN":["1432-0851"],"issn-type":[{"value":"1432-0851","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,3]]},"assertion":[{"value":"10 October 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 December 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 January 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Prospective cohort:\n                      All participants providing written informed consent.\n                      Retrospective cohort:\n                      An informational summary was presented on our hospital's website and the patients who did not consent were excluded.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"This study was performed in line with the principles of the Declaration of Helsinki. Approval was granted by the Ethics Committee of Nagoya University (2018\u20130400).","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}],"article-number":"70"}}